3 ms·
Disclaimer: medicine isn't my background, so the following comment could be partially or entirely groundless. --- So I just took a crack at the concept PDF an
by eganist 11y ago
Disclaimer: medicine isn't my background, so the following comment could be partially or entirely groundless.
---
So I just took a crack at the concept PDF and the rest of the literature on the site, and there's nothing that I can find which mitigates the risk of flagging a slow-growing or self-regressing tumor as something worthy of attention.
I say this because mammogram recommendations were only recently changed due to the potential adverse health risks stemming from treating tumors which might never progress to a severity warranting treatment [1] as well as tumors which might spontaneously regress [2]. If some of the newer oncology theories suggesting high tumor occurrence and anti-cancer immune responses are correct (my google-fu didn't help me here, so someone else might want to help me with the source), then as a result of Grail, you might start having a bunch of people freak out and undergo unnecessarily heavy treatments for tumors which might otherwise never become cancerous.
That said, I could be entirely wrong, and I wouldn't be surprised if they're specifically working on mitigating this risk as one component of making this screen viable.
[1]http://www.webmd.com/breast-cancer/features/new-mammogram-screening-guidelines-faq?page=2 http://www.webmd.com/breast-cancer/features/new-mammogram-sc...
[2]http://archinte.jamanetwork.com/article.aspx?articleid=773446 http://archinte.jamanetwork.com/article.aspx?articleid=77344...
- johntb86 11y agoI guess the difference is that mammograms tell you that there's some sort of tumor, while sequencing the blood can give a better idea of what's wrong with it. If you know what oncogenes it has then hopefully you can figure out how it's going to progress.
- riahi 11y agoMammograms/other imaging also tell you where the tumor is. Until we have perfect chemotherapy, local treatment with surgery and radiation will remain standard of care. To perform those, you need to know where the tumor is. I find the utility of this test will be in monitoring for recurrence, perhaps reducing the standard every 3 month restaging examinations; however, once it starts going up, you'll need advanced imaging again to see if it's local or metastatic recurrence.
- deleted 11y ago[deleted]